National Health (Pharmaceutical Benefits – Therapeutic Groups) Amendment Determination 2012 (No. 1) (No. PB 16 of 2012) (Cth)
National Health (Pharmaceutical Benefits – Therapeutic Groups) Amendment Determination 2012 (No. 1)
Instrument number PB 16 of 2012
National Health Act 1953
I, ADRIANA PLATONA, Assistant Secretary, Pharmaceutical Evaluation Branch, Pharmaceutical Benefits Division, Department of Health and Ageing, delegate of the Minister for Health, make this determination under subsection 84AG(1) of the National Health Act 1953.
Dated 20 March 2012
ADRIANA PLATONA
Assistant Secretary
Pharmaceutical Evaluation Branch
Pharmaceutical Benefits Division
Department of Health and Ageing
Name of Determination
(1) This Determination is the National Health (Pharmaceutical Benefits – Therapeutic Groups) Amendment Determination 2012 (No. 1).
(2) This Determination may also be cited as PB 16 of 2012.
Commencement
This Determination commences on 1 April 2012.
3 Amendments to PB 1 of 2010
Schedule 1 amends the National Health (Pharmaceutical Benefits – Therapeutic Groups) Determination 2010 (PB 1 of 2010).
Schedule 1 Amendments
[1] Section 4, omit definition of CCB group
[2] Section 4, omit definition of Statins group
[3] Schedule 1, Part 1
omit:
1
Captopril
2
Enalapril
[4] Schedule 1, Part 1
omit:
4
Lisinopril
5
Perindopril
6
Quinapril
7
Ramipril
8
Trandolapril
[5] Omit entry for Schedule 1, Part 3
[6] Schedule 1, Part 4
omit:
2
Famotidine
[7] Schedule 1, Part 5
omit:
2
Lansoprazole
3
Omeprazole
4
Pantoprazole
[8] Omit entry for Schedule 1, Part 6
Note
1. All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the Legislative Instruments Act 2003. See
0
0
0